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Abstract: Synthetic cannabinoid receptor agonists (SCRAs) remain popular drugs of abuse. As many
SCRAs are known to be mostly metabolized, in vitro phase I metabolic profiling was conducted of the
two indazole-3-carboxamide SCRAs: CUMYL-THPINACA and ADAMANTYL-THPINACA. Both
compounds were incubated using pooled human liver microsomes. The sample clean-up consisted
of solid phase extraction, followed by analysis using liquid chromatography coupled to a high
resolution mass spectrometer. In silico-assisted metabolite identification and structure elucidation
with the data-mining software Compound Discoverer was applied. Overall, 28 metabolites were
detected for CUMYL-THPINACA and 13 metabolites for ADAMATYL-THPINACA. Various mono-,
di-, and tri-hydroxylated metabolites were detected. For each SCRA, an abundant and characteristic
di-hydroxylated metabolite was identified as a possible in vivo biomarker for screening methods.
Metabolizing cytochrome P450 isoenzymes were investigated via incubation of relevant recombinant
liver enzymes. The involvement of mainly CYP3A4 and CYP3A5 in the metabolism of both substances
were noted, and for CUMYL-THPINACA the additional involvement (to a lesser extent) of CYP2C8,
CYP2C9, and CYP2C19 was observed. The results suggest that ADAMANTYL-THPINACA might be
more prone to metabolic drug−drug interactions than CUMYL-THPINACA, when co-administrated
with strong CYP3A4 inhibitors.
Keywords: synthetic cannabinoid receptor agonists; in vitro metabolism; high resolution mass
spectrometry; Compound Discoverer
1. Introduction
Synthetic cannabinoid receptor agonists (SCRAs) are a prominent class within the
world of new psychoactive substances (NPS). In recent years, SCRAs, together with syn-
thetic cathinones, were the predominantly seized classes of NPS in Europe [1]. SCRAs
encompass a large variety of structurally diverse compounds with binding affinities to
the cannabinoid receptors 1 and 2 (CB1 and CB2). Particularly via interaction with CB1,
most SCRAs present cannabimimetic effects similar to ∆9-tetrahydrocannabinol (THC), the
major psychoactive compound in cannabis [2–4]. The typically higher binding affinities
of SCRAs as full agonists at CB1 and CB2, when compared to THC, are attributed to the
often-observed increased potency, but also toxicity, of these compounds. Nevertheless,
data on the pharmacology and toxicity of SCRAs is still limited [2,5,6]. Several cases of
severe intoxication, including lethal outcomes, have been associated with the intake of
SCRAs, thus underlining the public health threat posed by these compounds [7–12].
SCRAs are classified based on their chemical structure [2]. In recent years, many
indazole- and indole-carboxamide-derived SCRAs have been reported, with 5F-MDMB-
PINACA (5F-ADB), 5F-MDMB-PICA, and MDMB-4en-PINACA being frequently reported
after detection in diverse formulations, ranging from shredded herbs that have been
sprayed with SCRAs (“spice”), infused papers, e-liquids, and bulk powders [13–15]. Since
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the end of 2019, drug checking services in Switzerland have increasingly reported SCRAs
fortified THC-low cannabis [16]. As these illicit products are generally sold as the nonal-
tered natural drug hemp, consumers unknowingly consuming SCRAs are clearly posed
with an increased health threat. As the emergence of SCRAs on the drug market is con-
stantly changing, as well as showing regional differences (for instance due to varying legal
frameworks), it is important that analytical laboratories are constantly developing their
analytical approach to SCRAs. Urine is a matrix that is often used for screening procedures
in clinical and forensic toxicology due to favorable accessibility, higher concentrations of
the substance of interest, and often longer detection windows when compared to blood.
However, many SCRAs are known to be extensively metabolized, leading to a significant
decrease or even lack of the parent compound in urine. As a consequence, metabolism
studies identifying suitable target metabolites of NPS are inevitable [17–20].
CUMYL-THPINACA is classified as an indazole-3-carboxamide SCRA. A patent for
CUMYL-THPINACA was issued in 2014 [21]. The cumyl-moiety is part of several SCRAs,
as in, for example, CUMYL-BICA, 5F-CUMYL-PINACA, 5F-CUMYL-PICA, and CUMYL-
4CN-BINACA [22]. The metabolism of several cumyl-bearing SCRAs has been investigated
before [23–26], therefore the obtained results for CUMYL-THPINACA expand the current
knowledge on the metabolism of members of this diverse subgroup. Considering its activity,
Asada et al. synthesized CUMYL-THPINACA, finding strong activity at CB1 and CB2 [27].
This was confirmed via radioligand binding studies conducted by Schoeder et al. that
showed high binding affinities of CUMYL-THPINACA at both CB1 (Ki = 1.23 ± 0.20 nM)
and CB2 (Ki = 1.38 ± 0.86 nM) [28]. Even though these data on the affinity and activity of
CUMYL-THPINACA exist, metabolic profiling, resulting in suggested biomarkers for the
detection of the consumption of CUMYL-THPINACA, has, to the best of our knowledge,
not been conducted yet.
ADAMANTYL-THPINACA, also referred to as ATHPINACA, is structurally related
to CUMYL-THPINACA and AKB48 (APINACA). The adamantyl-moiety can be connected
to the rest of the molecule, yielding two positional isomers of ADAMANTYL-THPINACA,
which are referred to as isomer 1 [N-(1-adamantyl)] and isomer 2 [(N-(2-adamantyl)].
This study focusses on isomer 1, if not further specified. ADAMANTYL-THPINACA
was first reported by EMCDDA’s Early Warning System after it appeared in Slovenia in
2015 [29], followed by Hungary in 2016 [30]. Recently, a study was published focusing
on the metabolism of adamantyl-positional isomers of SCRAs, including first data on
both isomers of ADAMANTYL-THPINACA. Metabolites were produced via incubation
of pooled human liver microsomes (pHLM) and nine metabolites resulting from mono-,
di-, and tri-hydroxylation were identified for isomer 1 of ADAMANTYL-THPINACA.
Additionally, two glucuronidated metabolites were identified [31].
In this study, we present the phase I in vitro metabolic profiling of CUMYL-THPINACA
and ADAMANTYL-THPINACA, applying two experimental set-ups. First, both SCRAs
were incubated using pHLM, resulting in structural elucidation and identification of poten-
tial in vivo biomarkers of the detected metabolites. The incubation of active pharmaceutical
ingredients with pHLM, amongst other in vitro models (such as human hepatocytes), is an
established procedure for initial characterization of human metabolism [18,20,32] and there-
fore highly valuable for the study of SCRAs, for which information on the metabolism and
suitable biomarkers is often lacking [20]. Metabolites as certified reference standards are
often not available. Therefore, in vitro metabolism studies are a good alternative to incor-
porating metabolites into screening methods. Second, the cytochrome P450 enzymes (CYP)
responsible for the phase I metabolism of the studied SCRAs were identified via incubation
of a pallet of recombinant CYP isoforms (rCYP), thus expanding the present knowledge on
the metabolism of ADAMANTYL-THPINACA as reported by Kadomura et al. [31]. Infor-
mation on the metabolizing CYP isoforms gives the opportunity to predict the likelihood
of metabolic drug−drug interactions or adverse events due to CYP polymorphisms [33–
37]. A study conducted by Holm et al. showed that CYP3A4 was mainly responsible
for the biotransformation of AKB48, an SCRA structurally related to ADAMANTYL-
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THPINACA. Nevertheless, specific CYP isoforms involved in the metabolism of SCRAs
are often understudied and have, so far, not been investigated for CUMYL-THPINACA or
ADAMANTYL-THPINACA.
Due to the diversity and large numbers of NPS emerging on the drug market, the
rapid identification of target metabolites for screening procedures is urgently needed.
High-resolution mass spectrometry (HR-MS) data analysis software is gaining importance,
as in silico-assisted workflows enable higher throughput and are able to markedly facilitate
metabolite identification [38,39]. In this study, data analysis was assisted by the Compound
Discoverer (Thermo Fisher Scientific, Reinach, Switzerland) software, which has already
been proven helpful for metabolite identification and structure elucidation in previously
published studies [38,40–43].
2. Results and Discussion
2.1. Metabolite Identification for CUMYL-THPINACA and ADAMANTYL-THPINACA after
Incubation with pHLM and rCYP
Functionality of the pHLM assay was assured by incubations of UR-144 (positive con-
trol) and subsequent detection of its N-(5-hydroxypentyl) and N-pentanoic acid metabolites.
Negative controls did not result in any metabolite signals.
CUMYL-THPINACA and ADAMANTYL-THPINACA were extensively metabolized,
resulting in a substantial decrease of the parent compound in the incubation mixture.
Several metabolites resulting from mono-, di-, tri-hydroxylation, desaturation (most likely
via hydroxylation followed by dehydration), and carbonylation, as well as combina-
tions thereof, were identified. A summary of all detected metabolites and artefacts, and
the results obtained via rCYP incubation, are shown in in Tables 1 and 2 (for CUMYL-
THPINACA) and Tables 3 and 4 (for ADAMANTYL-THPINACA).
2.2. In-Source Water Loss of Metabolites
As a consequence of using electrospray ionization (ESI), in-source-fragmentation
processes may occur [39–42]. For example, the observed alleged metabolites, presenting
a mass shift of +13.9838 Da in comparison to the parent compound, may result from ei-
ther hydroxylation in combination with desaturation (e.g., di-hydroxylation followed by
dehydration) or carbonylation. However, the corresponding signals may also arise from
in-source water loss, resulting from the cleavage of aliphatic hydroxyl-groups (e.g., at the
4-methyl-tetrahydropyran- and adamantyl-moiety). In-source water loss was considered
as likely, where (i) a hydroxylated metabolite was detected, exhibiting a hydroxyl group
at a position predestined for in-source water loss, (ii) a co-eluting signal was identified,
presenting a dehydration-specific mass shift of −18.0153 Da (-H2O), and (iii) after fragmen-
tation, when the type and position of biotransformation were identical for the hydroxylated
metabolite and the alleged artefact. For example MC21, a metabolite produced by mono-
hydroxylation at the 4-methyl-tetrahydropyran-moiety (i) was detected, but additionally a
signal at the corresponding retention time (Rt) with mass shift of [M + H]+ −18.0153 Da
was found (ii), which exhibits dehydration at the 4-methyl-tetrahydropyran-moiety (iii).
Therefore, this signal was classified as an artefact (MCArt4).
The diversity in the hydroxylation patterns of metabolites, especially in cases of two or
three concurrent hydroxylations, makes the evaluation of in-source processes highly com-
plex. The observed results suggest that the susceptibility for in-source water loss consider-
ably varies between aliphatic structures (e.g., adamantyl versus 4-methyl-tetrahydropyran).
This becomes obvious when comparing the peak areas of genuine metabolites and the cor-
responding in-source artefacts. In the case of MA2 (hydroxylated at the adamantyl-moiety)
the corresponding artefact (MAArt1) showed a 6.8 times higher signal than observed for
MA2 itself. In comparison, MC21 (hydroxylated at the 4-methyl-tetrahydropyran-moiety)
exhibited an in-source dehydration signal of roughly the same intensity as that observed for
MC21. Additionally, positional isomers of hydroxylations within a moiety led to varying
levels of observed water loss. For instance, when investigating the metabolite cluster
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MC8a-e (consisting of several co-eluting di-hydroxylated metabolites, bearing a hydroxyl-
group at the 4-methyl-tetrahydropyran-moiety), in-source water loss varied from excessive
(artefact signal [MCArt2a–b] > metabolite signal) to not detectable.
In this study, several hydroxylated metabolites of CUMYL-THPINACA and one
of ADAMANTYL-THPINACA were prone to in-source dehydration, in most cases at-
tributable to the instability of the hydroxylated 4-methyl-tetrahydropyran-moiety. This
most likely resulted in the identification of several artefacts that are discussed in the cor-
responding chapters referring to the genuine metabolites. In addition, several signals
were detected lacking a hydroxylated counterpart, therefore not meeting the above-stated
criteria for in-source water loss—they were thus classified as genuine metabolites produced
by hydroxylation and desaturation (MC3, MC6, MC12, MC17, MA3, MA8, MA11) or
carbonylation (MC13, MC15, MC18, MC20, MC22, MA13, MA10). However, the possibility
remains, that the hydroxylated original metabolite was prone to complete in-source water
loss, i.e., the original parent ion was no longer detectable. In the context of analytics
and the herein presented aims, the focus of this study lies in the identification of suitable
biomarkers, which may include highly abundant artefacts resulting from true metabolites.
As in-source fragmentation is often seen as an unwanted ESI byproduct, it has also been
proposed that in-source-fragment information can improve metabolite identification [44].
However, it must be kept in mind, that the occurrence of in-source-fragmentation processes
may also depend on the instrument used, instrument configurations, and ESI conditions.
2.3. Metabolic Profiling of CUMYL-THPINACA
The fragmentation of CUMYL-THPINACA resulted in three diagnostic fragments
at m/z 119.0855, representing the cumyl-moiety, m/z 260.1394, referring to the unaltered
1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide structure, and m/z 243.1128, repre-
senting the 1-(tetrahydropyranyl-4-methyl)-indazole-3-acylium-ion. A total of three mono-
hydroxylated (MC19a–b, MC21), eight di-hydroxylated (MC1, MC8a-e, MC14, MC16), and
eight tri-hydroxylated (MC2a–b, MC4, MC5, MC7, MC9, MC10, MC11) metabolites were
detected (see Table 1). The di-hydroxylated metabolite MC16, presenting with highest peak
areas in the conducted experiments, is suggested as a suitable target in screening procedures.
Additional minor metabolites were produced via either hydroxylation with concurrent de-
hydration, referred to as mono-/di-hydroxylated and desaturated metabolites, or carbony-
lation. In this context, two mono-hydroxylated and desaturated metabolites (MC12, MC17)
and two di-hydroxylated and desaturated metabolites (MC3, MC6) were identified. Finally,
carbonylation led to the production of one metabolite (MC22) and mono-hydroxylation in
combination with carbonylation resulted in four metabolites (MC13, MC15, MC18, MC20).
In-source water loss could not be ruled out for some metabolites; thus, these signals were
classified as artefacts (MCArt1, MCArt2a–b, MCArt4, MCArt5). Through conduction of a
derivatization experiment, employing iodomethane as the methylating agent, the location
of the hydroxyl-groups could be narrowed down to the indazole-core. The main site for bio-
transformation in regard to number of individual metabolites as well as when considering
the most abundant metabolites was the 4-methyl-tetrahydropyran-moiety, while oxidation
of the cumyl-moiety was less often observed. There are several other studies investigating
the metabolism of SCRAs containing a cumyl-moiety [22,23,26]. These aforementioned
studies also concluded that the cumyl-moiety was not the main site of metabolism. A
chromatogram showing the mass traces of all metabolites is depicted in Figure 1 and the
proposed metabolic pathway of CUMYL-THPINACA is visualized in Figure 2. MS2 spectra
of CUMYL-THPINACA and the three most abundant metabolites, including proposed
fragments, are shown in Figure 3.
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Figure 2. Proposed metabolic pathway for CUMYL-THPINACA.
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Figure 3. MS2 spectra of CUMYL-THPINACA and its three most abundant metabolites (MC12, MC16, and MC22, shown 
in order of decreasing intensity). The proposed fragments leading to the respective signals are shown on the right. 
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MC19a is mono-hydroxylated at the cumyl-moiety, as a fragment at m/z 135.0804
was detected. For M19b and MC21, mono-hydroxylation at the 1-(tetrahydropyranyl-4-
methyl)-indazole-3-carboxamide structure was detected instead (m/z 276.1343). Due to the
observation of in-source dehydration (MCArt3 and MCArt4), and as derivatization did not
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alter the signals of MC19b and MC21, the location of the hydroxyl groups are suggested
to be located at the unsaturated 4-methyl-tetrahydropyran-moiety. MCArt3 and MCArt4
are signals matching the criteria defined in chapter 2.2, and thus are classified as artefacts
resulting from in-source dehydration of MC19b and MC21. Fragmentation of MCArt3
and MCArt4 showed desaturation at the 4-methyl-tetrahydropyran-moiety (m/z 258.1237),
which corresponds to the location of mono-hydroxylation of the co-eluting metabolites
MC19b and MC21.
2.3.2. Di-Hydroxylation
The most abundant metabolite after 2 h of incubation was the di-hydroxylated metabo-
lite MC16. For MC16, the unaltered cumyl-moiety was detected. As a dehydration reaction
was identified during fragmentation, resulting in a fragment at m/z 274.1186, it was con-
cluded that the second hydroxyl-group is located at the 4-methyl-tetrahydropyran-moiety.
The location of the second hydroxyl-group at the indazole-core was verified after derivati-
zation. When fragmenting the proposed product of methylation of MC16 at m/z 424.2231
(mass shift of 14.0157 Da), a specific fragment corresponding to the 1-(tetrahydropyranyl-4-
methyl)-indazole-3-carboxamide-moiety which had been di-hydroxylated and methylated,
was detected at m/z 306.1448.
MC1, MC8a-e, and MC16 are additional metabolites resulting from di-hydroxylation.
MC1 is produced via di-hydroxylation at the cumyl-moiety, indicated by a fragment at
m/z 151.0754. Several isomers were detected arising from concurrent mono-hydroxylation
at the cumyl-moiety and the 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide-
moiety, resulting in the metabolite cluster MC8a-e. As the fragment at m/z 258.1237 was
found throughout (produced via water loss from the 4-methyl-tetrahydropyran-moiety),
the hydroxyl-group of the metabolites MC8a-e were concluded to be located at the 4-
methyl-tetrahydropyran-moiety. Co-eluted with the metabolite cluster MC8a–e, MCArt2a–
b (consisting of two fused peaks), was detected. After fragmentation of MCArt2a–b, the
location of one hydroxyl-group was identified at the cumyl-moiety and desaturation was
found at the 4-methyl-tetrahydropyran-moiety. Due to the matching type and location of
the biotransformation between the original metabolites MC8a-e and MCArt2a–b, the origin
of the signal leading to MCArt2a–b was defined as in-source water loss. Finally, MC14 is
di-hydroxylated at the di-hydroxylated cumyl-moiety, as the diagnostic fragment at m/z
151.0754 was identified.
2.3.3. Mono-Hydroxylation and Additional Desaturation and Carbonylation
MC12, MC17, and MC22 are all metabolites sharing the parent ion at m/z 392.1969.
As no co-eluting di-hydroxylated metabolites exhibiting the same patterns were detectable
(considering the type and location of biotransformation), in-source water loss as the ori-
gin of the corresponding signals was ruled out for these metabolites. MC12 and MC17
presented a fragment at m/z 256.1081 that resulted from the dehydration of the already
desaturated 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide-moiety. Due to the
observed desaturation, MC14 and MC19 were classified as mono-hydroxylated and de-
saturated at the 4-methyl-tetrahydropyran-moiety. The absence of phenolic hydroxyl
groups was confirmed via derivatization experiments, as no signal decline of the parent
ion was observed. MC22 did not present a dehydration reaction during fragmentation
as only the fragments with m/z 274.1186 (desaturated 1-(tetrahydropyranyl-4-methyl)-
indazole-3-carboxamide structure) and m/z 257.09134 (acylium-ion after cleavage of the
C-N bond) were detected. Therefore, M22 was concluded to be carbonylated at the 4-
methyl-tetrahydropyran-moiety.
2.3.4. Tri-Hydroxylation
MC2a–b and MC4 are di-hydroxylated at the cumyl-moiety, as verified by detection of
the fragment at m/z 151.0754. MC2a–b and MC4 also present a fragment at m/z 408.1918
as a result of water loss during fragmentation of the otherwise intact structure. Due to the
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observed water loss, the location of the one hydroxyl group is situated at the 4-methyl-
tetrahydropyran-moiety. MC5 was observed to be mono-hydroxylated at the cumyl-moiety,
showing the diagnostic fragment at m/z 135.0804. The additional fragment at m/z 256.1081,
resulting from two dehydration reactions of the di-hydroxylated 1-(tetrahydropyranyl-4-
methyl)-indazole-3-carboxamide structure, verifies the positions of the two other hydroxyl
groups at the 4-methyl-tetrahydropyran-moiety. In-source water loss of MC5, leading to
the signal of MCArt1, could not be ruled out, due to the proximity of MC5 and the observed
signal of MCArt1, which also has one hydroxyl-group at the cumyl-moiety (m/z 135.0804)
but is hydroxylated and additionally desaturated at the tetrahydropyran-moiety. Thus,
MCArt1 was defined as a possible artefact.
Mono-hydroxylation at the cumyl-moiety was also observed for MC7. As for MC7,
only one dehydration reaction was detected, indicated by the fragment at m/z 274.1186.
Observed fragments for MC7 indicated mono-hydroxylation at the cumyl-moiety, the
indazole-core, and at the 4-methyl-tetrahydropyran-moiety. This was also confirmed via
the derivatization experiment, as the methylated product of MC7 was detected, presenting a
diagnostic fragment at m/z 306.1448, which represents the di-hydroxylated and methylated
1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide-moiety. MC9 is di-hydroxylated
at the cumyl-moiety, as shown by the fragment at m/z 151.0754. Additionally, a fragment at
m/z 258.1237 was detected, which was the dehydration product of the 1-(tetrahydropyranyl-
4-methyl)-indazole-3-acylium-ion, thus indicating the location of the third hydroxyl group
at the 4-methyl-tetrahydropyran-moiety. MC10 is suggested to be di-hydroxylated at the 4-
methyl-tetrahydropyran-moiety, but additionally mono-hydroxylated at the indazole-core.
Further, an ion corresponding to the product of tri-hydroxylation and methylation of MC10
at m/z 440.2180 was detected after derivatization. Fragmentation of this methylated metabo-
lite produced a diagnostic ion at m/z 322.1397, referring to the methylated tri-hydroxylated
1-(tetrahydropyranyl-4-methyl)-indazole-3-acylium-ion, and thus verifying the location of
one hydroxyl group at the unsaturated indazole-region. MC11 is tri-hydroxylated at the 1-
(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide structure, as the fragment standing
for the tri-hydroxylated 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide-moiety
(m/z 308.1241) was detected. Additionally, this moiety produced further fragments, after
one (m/z 290.1135), two (m/z 272.1030), and three dehydrations (m/z 254.0924). Derivati-
zation did not result in a decline of the MC11 signal, thus confirming the location of all
three hydroxyl-groups at the unsaturated 4-methyl-tetrahydropyran-moiety.
2.3.5. Mono-Hydroxylation and Additional Desaturation and Carbonylation
MC3 is most likely formed via metabolic tri-hydroxylation (MC5) and concurrent de-
hydration, resulting in a di-hydroxylated and desaturated molecule. MC3 presented a frag-
ment at m/z 135.0804, which represents the mono-hydroxylated cumyl-moiety. The desatu-
ration reaction and the second hydroxyl group are located at the 4-methyl-tetrahydropyran-
moiety, as the fragment at m/z 256.1081 was detected—resulting from additional dehy-
dration of this moiety. For MC6, the location of both hydroxyl-groups was found to be at
the cumyl-moiety, as a fragment at m/z 151.0754 was detected. An additionally observed
fragment at m/z 258.1237 was attributed to the desaturated 1-(tetrahydropyranyl-4-methyl)-
indazole-3-acylium-ion.
MC13 and MC15 are classified as mono-hydroxylated and carbonylated metabolites.
With the diagnostic ion at m/z 135.0804, both are identified as to be mono-hydroxylated
at the cumyl-moiety. Due to the lack of the dehydration reaction during occurring frag-
mentation, it is suggested that MC13 and MC15 are therefore carbonylated at the 4-methyl-
tetrahydropyran-moiety. Mono-hydroxylation in combination with carbonylation was
also observed for MC18. Due to the presence of the fragment at m/z 119.0855, and as
MC18 was not methylated during derivatization, proving the absence of phenolic hy-
droxyl groups, it is assumed that hydroxylation and carbonylation must be located at the
4-methyl-tetrahydropyran-moiety. The fragment at m/z 290.1135 represents the mono-
hydroxylated and carbonylated 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide
Metabolites 2021, 11, 470 11 of 25
structure. The fragment at m/z 272.1030 is produced by additional dehydration and a
fragment at m/z 273.087 results from nitrogen cleavage. MC20 presented two diagnostic
ions at m/z 260.1394 and m/z 243.1128, representing the unaltered 1-(tetrahydropyranyl-
4-methyl)-indazole-3-carboxamide-moiety. The fragment at m/z 149.0597 represents the
cumyl-moiety that has been mono-hydroxylated and carbonylated. With the methylated
product of MC21, the location of the hydroxyl was assigned at the phenyl-ring of the
cumyl-moiety. In-source water loss, resulting in an additional signal associated with MC3,
MC6, MC13, MC17, MC18, and MC20, was not further considered, due to the lack of
corresponding tri-hydroxylated metabolites in the respective elution windows. The ob-
served later elution of metabolites MC18 and MC20 was in concordance with the suggested
carbonylation, as this biotransformation would result in less polar metabolites compared
to the product of di-hydroxylation and desaturation.
2.3.6. Identification of the Primarily Involved CYP Isoenzymes
The results obtained showed that CYP3A4 and CYP3A5 are primarily involved in
the metabolism of CUMYL-THPINACA, followed by CYP2D6, CYP2C8, and, to a much
lesser extent, by CYP2C19. The involvement of CYP2C9, CYP1A2, and CYP2B6 was also
observed. Signals at the retention times of MCArt3 and MCArt4, presenting an area ratio
(peak area/internal standard (ISTD) area) of <0.1, were detected in the negative control as
well as in the incubation mixture of CYP2E1 and CYP2A6. As these were the only signals
detected for CYP2E1 and CYP2A6, it suggests that CYP2E1 and CYP2A6 did not show
any metabolic activity for CUMYL-THPINACA. Two metabolites (MC4 and MC5), which
were observed after incubation using pHLM, could not be detected after incubation with
rCYP (tested with different incubation times), most likely due to these metabolites being
produced via a more complex pathway; the involvement of a combination of different CYP;
or at concentration levels below the limit of detection. These results are summarized in
Table 2.
CYP3A4 is an important CYP isoform with regard to abundancy in the human liver
as well as the majority of drugs being known to be substrates of CYP3A4. Overall, due
to the primary involvement of CYP3A4, drug−drug interactions may be observable in
combination with strong CYP3A4 inhibitors (e.g., azole-antifungals) [45]. Nevertheless,
due to the involvement of further CYP isoforms (e.g., CYP2D6, CYP2C8, and CYP2C19),
this risk is most likely reduced.
Table 2. Results of the incubation of CUMYL-THPINACA with rCYP. Listed area ratios (absolute peak are (metabo-
lite)/absolute peak area (ISTD)) are classified as follows: (+): <0.1, +: ≥0.1–≤1, ++: >1–≤5, +++: >. Where the negative
control contained trace amounts of metabolites in a comparable amount, as in the samples after incubation, the result is
marked as: (+) *.
ID
3A4 3A5 2D6 2C8 2C9 2C19 2B6 1A2 2E1 2A6 NegativeControl
n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2
MC1 (+) (+) - - - - - - - - -
MC2a–b + (+) - - - - - - - - -
MC3 (+) - - - - - - - - -
MC4 - - - - - - - - - - -
MCArt1 (+) (+) - - - - - - - - -
MC5 - - - - - - - - - - -
MC6 (+) (+) - - - - - - - - -
MC7 (+) (+) - - - - - - - - -
MC8a–e + + (+) (+) (+) (+) - - - - -
MC9 (+) - - - - - -
Metabolites 2021, 11, 470 12 of 25
Table 2. Cont.
ID
3A4 3A5 2D6 2C8 2C9 2C19 2B6 1A2 2E1 2A6 NegativeControl
n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2
MCArt2a–b + + (+) (+) - (+) - - - - -
MC10 + + - - - - - - - - -
MC11 + (+) - - - - - - - - -
MC12 ++ + - - - - - - - - -
MC13 (+) - - - - - - - - - -
MC14 + + (+) (+) - (+) - - - - -
MC15 (+) - - - - - - - - -
MC16 ++ ++ + (+) - (+) - - - - -
MC17 + (+) - - - - - - - - -
MC18 + (+) - - - - - - - - -
MC19a–b +++ ++ ++ + (+) + (+) (+) - - -
MCArt3 +++ +++ +++ ++ + ++ + + (+) * (+) * (+) *
MC20 + (+) - - - - - - - - -
MC21 +++ +++ ++ ++ + ++ (+) (+) - - -
MCArt4 +++ +++ +++ +++ + +++ (+) * (+) * (+) * (+) * (+) *
MC22 ++ + (+) (+) - (+) - - - - -
2.4. Metabolite Identification for ADAMANTYL-THPINACA
ADAMANTYL-THPINACA was prone to hydroxylation at the adamantyl-moiety
and, to a lesser extent, at the 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide-
moiety. Extensive hydroxylation at the adamantyl-moiety has also been observed for
other adamantyl-bearing SCRAs [31,46,47]. Overall, one mono-hydroxylated (M12), three
di-hydroxylated (MA5, MA7, MA9), and four tri-hydroxylated (MA1, MA2, MA4, MA6)
were detected. During analysis, two artefacts were detected (MAArt1 and MAArt2),
resulting from in-source water loss of di- and a tri-hydroxylated metabolites. In-source
water loss was ruled out for three additional metabolites produced via hydroxylation with
concurrent desaturation (MA3, MA8, MA11) and mono-hydroxylation in combination with
carbonylation (MA10 and MA13). In this study, a total of 13 metabolites were detected
for ADAMANTYL-THPINACA (see Table 3). Kadomura et al. reported nine metabolites
resulting from phase I metabolism and two glucuronidated metabolites resulting from
phase II metabolism [31]. Regarding the previously reported phase I metabolites produced
via mono-, di-, and tri-hydroxylation, the results of our study are in good agreement
with theirs, with the exception of one additional tri-hydroxylated metabolite that was
not detected in our study. This was most probably due to insufficient chromatographic
resolution. However, Kadomura et al. did not present the herein observed metabolites
produced from hydroxylation in combination with desaturation (MA3, MA8, MA11) and
the two mono-hydroxylated and carbonylated metabolites (MA10 and MA13). In the
presented study, MA3 and MA8 were ranked as the third and fourth most abundant
metabolites, while the rest could be considered as minor metabolites, and thus more likely
of limited importance as biomarkers in the in vivo setting. In contrast to Kadomura et al.
we did not study the phase II metabolism.
A chromatogram showing the mass traces of all the above-mentioned metabolites
and signals in this study is given in Figure 4. Due to the high abundancy of the di-
hydroxylated metabolite MA9, this metabolite is suggested as a suitable biomarker for
urine screenings. Nevertheless, due to limitations of in vitro models, verification in vivo by
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ana-lysis of positive human urine samples is needed. The proposed metabolic pathway is
presented in Figure 5. Fragmentation of the parent compound ADAMANTYL-THPINACA
resulted in only one fragment at m/z 135.1168. Variation of the collision energies did not
result in more diagnostic ions for the parent compound (data not shown). Additional
diagnostic fragments were detected for the metabolites of ADAMANTYL-THPINACA.
The respective MS2 spectra of ADAMANTYL-THPINACA, incorporating the three most
abundant metabolites with their suggested fragments, are shown in Figure 6.




Figure 4. Chromatogram showing the mass traces of the detected metabolites (and artefacts) of ADAMANTYL-
THPINACA after 2 h of incubation. The traces are normalized globally, with a maximum at 12% of the base peak (MA9). 
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Figure 6. MS2 spectra of ADAMANTYL-THPINACA and its three most abundant metabolites. The proposed fragments 
leading to the respective signals are shown on the right. 
Table 3. Summary of all detected metabolites, and observed artefacts thereof, of ADAMANTY-THPINACA (listed in the 
order of the observed retention times). Shown are the suggested biotransformations, chemical formulas, calculated [M + 
H] of the parent ions and the corresponding product ions, as well as retention times, area after 2 h of incubation, and rank. 
ID Biotransformation Formula 






Rt (min) Area  
(n = 2) 
Rank 
MA1 di-hydroxylation at adamantyl, 
mono-hydroxylation at 4-
methyl-tetrahydropyran 
C24H31N3O5 442.2336 1.4 0.87 9.2 × 106 11 
  424.2221     
  259.1077     
  167.1067     
  149.0961     
  131.0855     
MA2 di-hydroxylation at adamantyl, 
mono-hydroxylation at 4-
methyl-tetrahydropyran 
C24H31N3O5 442.2336 −0.7 0.97 1.1 × 107 10 
  424.2221     
  259.1077     
  167.1067     
  149.0961     
  131.0855     
MAArt1 in-source water loss of MA2 C24H29N3O4 424.2231 −0.7 0.98 7.5 × 107  
  259.1077     
  241.1044     
  167.1067     
  149.0961     
   131.0855     





























































































































Figure 6. MS2 spectra of ADAMANTYL-THPINACA and its three most abundant metabolites. The proposed fragments
leading to the respective signals are shown on the right.
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Table 3. Summary of all detected metabolites, and observed artefacts thereof, of ADAMANTY-THPINACA (listed in the
order of the observed retention times). Shown are the suggested biotransformations, chemical formulas, calculated [M + H]
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MA11 Di-hydroxylation at adamantyl,
desaturation at
4-methyl-tetrahydropyran



















ADAMANTYL-THPINACA C24H31N3O3 394.2489 0.6 4.56 1.0 × 106 -
135.1167
2.4.1. Mono-Hydroxylation
MA12 is produced via mono-hydroxylation at the adamantyl-moiety, as shown by the
diagnostic fragment at m/z 151.1117.
2.4.2. Di-Hydroxylation
For MA7, the observed fragment of m/z 151.1117 indicated mono-hydroxylation at
the adamantyl-moiety. Therefore, the second hydroxyl group is located at the rest of the
molecule. Because derivatization did not change the signal intensity of the MA7 metabolites,
this suggests that the second hydroxyl-group is located at the 4-methyl-tetrahydropyran-
moiety. The di-hydroxylated metabolite MA9 was the most abundant metabolite. Due to
the fragment observed at m/z 167.1067, the location of both hydroxyl groups was assigned
to the adamantyl-moiety. Additional fragments consisted of two dehydration reactions of
the di-hydroxylated adamantyl moiety (m/z 149.0961 and m/z 131.0855) and the unaltered
1-(tetrahydropyranyl-4-methyl)-indazole-3-acylium-ion (m/z 243.1128). Two additional,
but less abundant, di-hydroxylated metabolites were detected, of which MA5 showed
a similar fragmentation pattern to MA9, thus being di-hydroxylated at the adamantyl-
moiety. As MAArt2, presenting fragments at m/z 149.0961 and m/z 131.0855 indicating
dehydration reactions at the hydroxylated adamantyl-moiety, co-eluted with the metabolite
MA9, MAArt2 was classified as an in-source artefact produced by dehydration of MA9.
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2.4.3. Mono-Hydroxylation and Additional Desaturation
The metabolite MA8 is produced via mono-hydroxylation at the adamantyl-moiety,
indicated by fragment m/z 151.1117. The observed desaturation was assigned to the rest of
the molecule (4-methyl-tetrahydropyran-moiety), even though the corresponding fragment
was not detected due to neutral loss. As MA8 did not co-elute with a di-hydroxylated
metabolite, which is mono-hydroxylated at the adamantyl-moiety as well as at the 4-methyl-
tetrahydropyran-moiety, this signal was classified as a genuine metabolite.
2.4.4. Tri-Hydroxylation
The two early-eluting metabolites, MA1 and MA2, were identified to be di-hydroxylated
at the adamantyl-moiety and mono-hydroxylated at the 1-(tetrahydropyranyl-4-methyl)-
indazole-3-carboxamide structure. For these two metabolites, the observed fragment
at m/z 167.2066 represents the di-hydroxylated adamantyl-moiety and the fragment at
m/z 259.1077 denotes the mono-hydroxylated 1-(tetrahydropyranyl-4-methyl)-indazole-
3-acylium-ion. As derivatization did not result in methylation of MA1 and MA2, it
was concluded that both metabolites are produced via hydroxylation at the 4-methyl-
tetrahydropyran-moiety. MAArt1 was detected via the parent ion at m/z 424.2231 and is
denoted as an in-source dehydration artefact. MAArt1 was identified to be di-hydroxylated
at the adamantyl-moiety (m/z 167.1067) and desaturated at the 4-methyl-tetrahydropyran-
moiety (m/z 259.1077). Due to the presence of the coeluting tri-hydroxylated metabolite
MA2, showing the same alterations, a potential contribution from MAArt1 to the observed
MA2 signal could not be ruled out. MA4 presented MS2 spectra with two fragments at m/z
260.1393 and m/z 243.1128, both indicating an unaltered 1-(tetrahydropyranyl-4-methyl)-
indazole-3-carboxamide moiety. It was consequently concluded that the adamantyl-moiety
was hydroxylated three times, despite the fragment representing this moiety not being de-
tected, due to neutral loss. The latest eluting tri-hydroxylated metabolite MA6 is produced
via mono-hydroxylation at the adamantyl-moiety, shown by the diagnostic fragment at
m/z 151.1117, and di-hydroxylation of the remaining molecule. One observed fragment of
MA6 at m/z 274.1184 is produced via dehydration of the 1-(tetrahydropyranyl-4-methyl)-
indazole-3-carboxamide-moiety. Therefore, one hydroxyl group must be located at the
4-methyl-tetrahydropyran-moiety. As no second dehydration reaction of this moiety was
detected, the third hydroxy group was proposed to be located at the indazole-core. The
location of the hydroxyl group at the indazole-moiety was verified via derivatization, as
the corresponding methylated metabolite MA6 was detected at m/z 456.2493. Additionally,
fragmentation of this product resulted in a fragment with m/z 288.1343, indicative of
the methylated and desaturated 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide-
moiety.
2.4.5. Di-Hydroxylation and Additional Desaturation, Mono-Hydroxylation and
Additional Carbonylation
Fragmentation of MA3 with [M + H]+ 424.2231 (m/z), resulted in a fragment at m/z
167.1067, indicating di-hydroxylation at the adamantyl-moiety. Additionally, the desaturated
4-methyl-tetrahydropyran-moiety was identified with the detected m/z 259.1077, a fragment
indicative of the desaturated 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxylicacid-moiety
after amide hydrolysis. Due to the lack of a tri-hydroxylated counterpart, in-source de-
hydration was not considered for MA3. The metabolite MA10 resulted in a fragment
at m/z 151.1117, representing the mono-hydroxylated adamantyl-moiety. A fragment
produced from subsequent water loss at the adamantyl-moiety was also detected at m/z
133.1012. Due to a lack of further fragments, as a result of neutral loss, it was concluded
that further sites of biotransformation are located elsewhere on the molecule. Potential
biotransformations resulting in the signal at m/z 424.2231 include di-hydroxylation and
desaturation (likely derived from dehydration of a tri-hydroxylated metabolite, which was
not detected) or mono-hydroxylation in combination with carbonylation. As derivatization
did not result in a decrease of the MA10-signal, hydroxylation at the indazole-region
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was ruled out. In conclusion, MA10 was defined as the product of mono-hydroxylation
at the adamantyl-region with concurrent mono-hydroxylation and desaturation or car-
bonylation at the 4-methyl-tetrahydropyran-moiety. Due to the later elution of MA10,
when compared to the detected tri-hydroxylated metabolites, in-source dehydration was
not considered. MA11 is a further metabolite with a parent ion at m/z 424.2231, in this
case as a result of di-hydroxylation and desaturation, as indicated by the detection of the
di-hydroxylated adamantyl-moiety at m/z 167.1067. As this fragment was observed, the
location of desaturation was concluded to be at the 4-methyl-tetrahydropyran-moiety. As
no corresponding tri-hydroxylated metabolites were detected within the MA11 elution
window, in-source dehydration of this metabolite is unlikely. MA13 is classified as a
product of mono-hydroxylation and carbonylation. This was concluded from the pres-
ence of m/z 260.1393 (unaltered 1-(tetrahydropyranyl-4-methyl)-indazole-3-carboxamide
structure) and m/z 165.0910 (mono-hydroxylation and carbonylation of the adamantyl-
moiety). An additional fragment (m/z 119.0855) was detected, assigned to the cleavage of
CO and dehydration of the mono-hydroxylated and carbonylated adamantyl-moiety. The
longer retention time of this metabolite when compared to hydroxylated and desaturated
metabolites is also in accordance with carbonylation, due to the expected lower polarity of
a carbonyl group in comparison to a hydroxyl group.
2.4.6. Identification of the Primarily Involved CYP Isoenzymes
As for CUMYL-THPINACA, CYP3A4 and CYP3A5 were found to mainly contribute
to the metabolism of ADAMANTYL-THPINACA (Table 4). In contrast to CUMYL-
THPINACA, limited metabolic activity of CYP2D6, and CYP2C8 was observed. CYP2C9
and CYP2C19 mediated the production of M12, but no other metabolites, thus leading to
the conclusion that these isoforms play a minor role in the metabolism of ADAMANTYL-
THPINACA. For CYP2B6, CYP1A2, CYP2E1 und CYP2A6, no metabolic activity could be
observed.
Experiments revealed CYP3A4 also to be the major metabolizing CYP for ADAMANTYL-
THPINACA. In comparison to CUMYL-THPINACA, far fewer CYP isoforms were involved
in ADAMANTYL-THPINACA metabolism. The intake of strong CYP3A4 inhibitors to-
gether with ADAMANTYL-THPINACA is more likely to pose a higher risk of metabolic
drug−drug interactions than CYP3A4 in combination with CUMYL-THPINACA.
Table 4. Summary of the incubation results of ADAMANTYL-THPINACA with rCYP. Area ratios (absolute peak are
(metabolite)/absolute peak area (ISTD)) are expressed as follows: (+): <0.1, +: ≥0.1–≤1, ++: >1–≤5, +++: >5. Where the
negative control contained trace amounts of metabolites in a comparable amount, as in the samples after incubation, the
result is marked as: (+) *.
ID
3A4 3A5 2D6 2C8 2C9 2C19 2B6 1A2 2E1 2A6 NegativeControl
n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2
MA1 + (+) - - - - - - - - -
MA2 + (+) - - - - - - - - -
MAArt1 ++ (+) - - - - - - - - -
MA3 ++ (+) - - - - - - - - -
MA4 + (+) - - - - - - - - -
MA5 + (+) (+) (+) - - - - - - -
MA6 (+) (+) - - - - - - - - -
MA7 + (+) (+) (+) - - - - - - -
MA8 + ++ + (+) - - - - - - -
MA9 +++ ++ (+) (+) - - - - - - -
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Table 4. Cont.
ID
3A4 3A5 2D6 2C8 2C9 2C19 2B6 1A2 2E1 2A6 NegativeControl
n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2 n = 2
MAArt2 ++ + (+) (+) - - - - - - -
MA10 (+) (+) - - - - - - - - -
MA11 (+) (+) - - - - - - - - -
MA12 + +++ ++ +++ + + (+) * (+) * (+) * (+) * (+) *
MA13 + (+) - - - - - - - - -
3. Materials and Methods
3.1. Chemicals and Reagents
LC-MS grade acetonitrile (ACN), methanol (MeOH), and water, and HPLC grade ace-
tone and 2-isopropanol (IPA) were obtained from Macherey-Nagel AG (Oensingen, Switzer-
land). Ammonium formate (>99.0%), ethyl acetate (EtOAc, HPLC grade), iodomethane
(stabilized with silver), and formic acid (98–100%) were purchased from Merck (Zug, Switzer-
land). Potassium carbonate (Ph. Eur.) was purchased from Carl Roth AG (Arlesheim,
Switzerland). Certified reference standards of UR-144, UR-144 N-(5-hydroxypentyl) metabo-
lite, UR-144 N-pentanoic acid metabolite, and d,l-11-Hydroxy-THC-D3 were purchased from
Lipomed AG (Arlesheim, Switzerland). CUMYL-THPINACA (N-(1-methyl-1-phenylethyl)-1-
(tetrahydropyran-4-ylmethyl)-1H-indazole-3-carboxamide; purity >97%) and ADAMANTYL-
THPINACA (N-(1-adamantyl)1-(tetrahydropyran-4-ylmethyl)-1H-indazole-3-carboxamide;
purity >93%) were kindly provided by the Zurich Forensic Science Institute (Switzer-
land) in solid form (as certified reference substances were not available at the time of
this work). Stock solutions were prepared at 1 mg/mL in MeOH for both compounds
and stored at −20 ◦C until use. Pooled human liver microsomes (donor pool > 20, 20
mg/mL protein content in 250 mM sucrose, specified total P450 enzyme content of 360
pmol/mg protein) and Gentest NADPH regenerating system solutions: A (containing
26 mM β-nicotinamide adenine dinucleotide phosphate [NADP+], 66m MD-glucose-6-
phosphate [Glc-6-P], 66mMmagnesium chloride [MgCl2] in water), and B (containing 40
U/mL Glc-6-P dehydrogenase [Glc-6-P-DH; EC 1.1.1.49] in sodium citrate) were purchased
from Corning (Amsterdam, The Netherlands). Human CYP3A4 (100 pmol/mg protein),
CYP2C9 (100 pmol/mg protein), CYP2E1 (100 pmol/mg protein), CYP3A5 (100 pmol/mg
protein), CYP2C8 (100 pmol/mg protein), CYP2B6 (100 pmol/mg protein), CYP2A6 (with
purified human cytochrome b5, 100 pmol/mg protein), CYP1A2 (770 pmol/mg protein),
CYP2D6 (142 pmol/mg protein), CYP2C19 (202 pmol/mg protein), CYP3A5, and CYP2B6
EasyCYP Bactosomes co-expressed with human CYP-reductase in Escherichia coli, and
membrane protein isolated from Escherichia coli host strain (EasyCYP control, 10 mg/mL
protein), were ordered from tebu-bio (Offenbach, Germany).
3.2. Microsomal Incubation with pHLM
CUMYL-THPINACA, ADAMANTYL-THPINACA were incubated in duplicate at
final concentrations of 10 µM in a total reaction volume of 1000 µL. Following the vendors
instructions (Corning), the incubation mixture consisted of 100 mM potassium phosphate
buffer (pH 7), 50 µL NADPH Regenerating System Solution A, and 10 µL NADPH Regen-
erating System Solution B. The percentage of organic solvent (MeOH) was limited to 0.4%
in the incubation mixture, thus no inhibition due to organic solvents was to be expected
(limit for MeOH defined by Corning: 1%). The reaction was started by the addition of 0.5
mg liver microsomes per assay to the reaction mixture that was then tempered to 37 ◦C.
Negative controls were prepared by replacing the pHLMs with an equivalent volume of
water and by incubating enzymes without the addition of SCRAs, while parallel incubation
of the SCRA UR-144 served as a positive control for the functionality of the incubation. The
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samples were then incubated at 37 ◦C in an Eppendorf ThermoStat C heating block. In a
preliminary experiment (data not shown) samples were drawn after 0.5 h, 1 h, 1.5 h and 2
h after incubation with pHLM. For the presented data, the samples were incubated for 2 h,
as this incubation time gave the best outcome with respect to number and concentration of
metabolites. The reaction was terminated by the addition of an equal volume of ice-cold
ACN to 400 µL of drawn sample. The samples were then centrifuged at room temperature
for five minutes at 13,400 rpm (approximately 9000× g) using an Eppendorf MiniSpin
centrifuge (Eppendorf, Schönenbuch, Switzerland). The supernatant was stored in glass
vials at −20 ◦C until sample cleanup.
3.3. Microsomal Incubation with rCYP
Substrate solutions (final concentration 10 µM) were incubated in 100 mM potassium
phosphate buffer (pH 7), containing a final reaction volume of 500 µL, containing 38 µL
NADPH regenerating solution A and 13 µL NADPH Regenerating Solution B. The reaction
was started by the addition 25 µL of the CYP-solutions (or negative control EasyCYP),
resulting in 0.5 mg protein per assay. Following the vendors instructions (tebu-bio), the
reaction was quenched—after incubating for 20 min at 37 ◦C—by addition of 400 µL ice-
cold ACN to 400 µL of drawn sample. Subsequently, the samples were centrifuged at
13,400 rpm (approximately 9000× g) for five minutes. The supernatant was stored in glass
vials at −20 ◦C until further processing.
3.4. Sample Preparation
For sample clean-up, a protocol was adapted from one developed for the analysis
of metabolites of SCRAs in urine, published by Gaunitz et al. [35]. In brief, 600 µL of the
supernatants of the precipitated samples were diluted 1:1 with 100 mM ammonium formate
buffer (pH 4). At this point the internal standard (ISTD) d,l-11-Hydroxy-THC-D3 was
added, resulting in a concentration of 100 ng/mL (final concentration at time of analysis,
with presumed 100% recovery, 300 ng/mL). Strata phenyl SPE cartridges obtained from
Phenomenex (Basel, Switzerland) were conditioned with 2 mL MeOH, 2 mL water, and
2 mL ammonium formate buffer (pH 4), prior to being loaded with the diluted samples.
After loading the samples, the cartridges were washed with 2 mL of 5:95 MeOH:water
(v/v) and dried for 15 min. Elution of the analytes was achieved with twice 2 mL of 85:15
EtOAc:IPA (v/v). Extracts were collected in glass tubes and the solvent was evaporated
until dryness at 40 ◦C under a gentle stream of nitrogen. Finally, the dried residues were
resolved in 200 µL of 1:1 ACN:water (v/v), centrifuged (2465× g, 15 min) and transferred
to HPLC-vials, thus resulting in a concentration by a factor of 3.
3.5. Derivatization Using Iodomethane
SPE extracts obtained from pHLM incubation experiments were solved in 200 µL
acetone and then transferred into glass-vials, which were prefilled with a spatula tip
(approximately 500 mg) of potassium carbonate. At this point 100 µL iodomethane was
added, the vials were closed, and the mixtures were incubated for 1 h at 60 ◦C. The
samples were transferred into a new vial using a glass Pasteur pipet omitting the insoluble
potassium carbonate. The samples were evaporated to dryness under a gentle nitrogen
stream at 60 ◦C, and reconstituted in 200 µL 1:1 ACN:water. A negative control was
conducted for both SCRAs, where the addition of iodomethane was omitted while the rest
of the experiment was kept as above.
3.6. Analysis
Chromatographic separation of the metabolites was achieved using a Dionex UltiMate
3000 ultra UHPLC system equipped with a Hypersil Gold (50 × 2.1 mm 1.9 µM) analytical
column, thermostatted at 40◦ C using a MutliSLEEVE column heater, all obtained from
Thermo Fisher Scientific (Reinach, Switzerland). Mobile phase A consisted of water with
0.1% (v/v) formic acid and mobile phase B of ACN with 0.1% (v/v) formic acid. After
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injection of 5 µL of the prepared sample the gradient commenced at 20% mobile phase
B, which then increased to 40% within 0.9 min and to 71% within the following 6 min,
after which the mobile phase B was increased to 100% during a time interval of 0.25 min
and held for 1 min. The system was then returned to the initial settings and held for 1.25
min, prior to the injection of the next sample. The mobile phase flow was 0.6 mL/min
throughout. The mobile phase flow during the first 0.1 min and after 7 min was directed to
the waste and not to the mass spectrometer by means of a bypass valve connected after the
column.
Subsequent analysis was undertaken with a Thermo Scientific Q Exactive HF Hybrid
Quadrupole-Orbitrap mass spectrometer equipped with a heated electrospray ionization
(HESI-II) source, obtained from Thermo Fisher Scientific (Reinach, Switzerland), operated
with a sheath gas flow rate of 50 arbitrary units (AU) and an auxiliary gas flow rate of 5
AU. The capillary temperature and auxiliary gas heater temperature were 200 ◦C and 350
◦C, respectively, and the spray voltage was set to 3.5 kV. Parent ions of metabolites were
screened using a full MS acquisition in positive ion mode and at a resolution of 120,000
full width at half-maximum (FWHM) at m/z 200, within a scan range from m/z 150 to m/z
1000. Metabolite identification was conducted by manual investigation of the raw data in
FreeStyle (version 1.7, SP1, Thermo Fisher Scientific, Reinach, Switzerland), assisted by
the Compound Discoverer (version 3.1, Thermo Fisher Scientific, Reinach, Switzerland)
software, by running an expected workflow (Forensics Expected w FiSh scoring), that
enables the screening for software predicted products generated by biotransformation of
a predefined compound. The software thus calculates the expected masses of common
phase I metabolites and searches for corresponding signals in the data. The program
additionally identifies background signals by comparison of blank samples and negative
control samples, which are then filtered out and, therefore, not considered.
In a subsequent analysis, the software-proposed metabolites were transferred into an
inclusion list for a full MS—data-dependent MS2 (dd-MS2) analysis. The resolution for this
measurement was set to 60,000 FWHM for the full MS analysis and 15,000 FWHM for the
dd-MS2 analysis. Normalized stepped collision energies of 10, 17.5, and 35 (normalized
to m/z 500 [z = 1]) were applied. In order to ensure fragmentation of low abundance
and close eluting isobaric compounds, the minimum automated33 gain control (AGC)
target to trigger an MS2 measurement was set to zero and dynamic exclusion was set to
one second. The generated MS2 spectra were investigated with the aid of Compound
Discoverer, which enables comparison of the obtained MS2 spectra to the theoretical in
silico generated MS2-spectra [38].
The criterion for metabolite identification was a mass accuracy <5 ppm for the pro-
posed parent ions and diagnostic fragments along with the plausibility of observed frag-
ments and observed retention times of metabolites in relation to each other. The bio-
transformations were identified by mass shifts of the detected fragments, indicative of
hydroxylation (+15.9994 Da per hydroxylation), desaturation (−2.01565 Da), carbonylation
(+13.9838 Da), dehydration (−18.0153 Da), and combinations thereof. The position of hy-
droxylation was narrowed down by a derivatization experiment employing iodomethane,
which selectively methylates aromatic hydroxyl-groups (i.e., cumyl- and indazole-moiety).
4. Conclusions
Incubation with pHLM yielded 28 metabolites for CUMYL-THPINACA and 13
metabolites for ADAMANTYL-THPINACA. The observed extensive metabolism of the
studied SCRAs again highlight, as previously observed for many other SCRAs, the need to
include the metabolites in screening procedures—particularly in urine. Both compounds
presented a highly abundant di-hydroxylated metabolite, which is recommended as a
suitable target for screening procedures. For both compounds, in-source dehydration
artefact formation was observed for a few hydroxylated metabolites, supporting the need
for in vitro studies prior to moving on to in vivo measurements. However, several metabo-
lites, sharing the same mass as the described dehydration artefacts, were identified. This
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emphasizes the requirement to thoroughly investigate all signals of potential metabolites
in order not to miss potential biomarkers. Furthermore, as some dehydration products
presented higher abundancies than the underlying metabolite, their detection may improve
investigations of substance use and they should, therefore, be included into screening pro-
tocols. However, such recommendations would need to be verified by means of analysis of
human urine samples.
The reported protocols, along with the instrumentation and software used, proved
to be beneficial for the investigation of SCRA metabolite profiles. The in silico tools were
invaluable in speeding up the elucidation of the metabolic profile of the studied SCRAs.
Concerning the metabolism, the involvement of mainly CYP3A4 along with CYP3A5, was
observed for both compounds. For CUMYL-THPINACA the additional involvement of
2D6, 2C8, and 2C19 was found (all to a lesser extent than for CYP3A4), making CUMYL-
THPINACA less susceptible for metabolism-based drug−drug interactions or the effects
of CYP-polymorphism. Due to the main involvement of CYP3A4 in the metabolism of
ADAMANTYL-THPINACA, metabolic drug−drug interactions in combination with a
strong CYP3A4 inhibitor are considered more likely with ADAMANTYL-THPINACA than
with CUMYL-THPINACA.
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